GlassScriptPhysician profile
Ashley L Pyle
NPI 1013115989
$997.35
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $24.25 · 2022: $33.00 · 2023: $278 · 2024: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $319.82 | 2019-2024 | Farxiga |
| Nxstage Medical, INC. | $160.86 | 2019-2024 | |
| Glaxosmithkline, LLC. | $144.52 | 2022-2023 | Jesduvroq, Benlysta |
| Baxter Healthcare | $94.46 | 2024 | |
| Horizon Therapeutics Plc | $77.32 | 2023 | Krystexxa |
| Vifor Pharma, INC. | $45.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.61 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $27.39 | 2023 | Lupkynis |
| Amgen INC. | $23.14 | 2023 | Parsabiv, Aranesp, Tavneos |
| Amicus Therapeutics, INC. | $23.10 | 2019 | |
| Travere Therapeutics, INC. | $18.58 | 2023 | |
| Fresenius USA Marketing, INC. | $17.49 | 2024 | Nxstage System One |
| Lilly USA, LLC | $16.40 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Pyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.